Rapamycin is a triene macrolide antibiotic,which demonstrates anti-fungal,anti-inflammatory,anti-tumor and immunosuppressive
properties.
Rapamycin has been shown to block T-cell activation and proliferation,as well as,the activation of p70 S6 kinase and exhibits strong
binding to FK506 binding proteins.
Rapamycin also inhibits the activity of the protein,mTOR(mammalian target of rapamycin) which functions in a signaling pathway to
promote tumor growth.
Rapamycin binds to a receptor protein (FKBP12) and the rapamycin/FKB12 complex then binds to mTOR and prevents interaction
of mTOR with target proteins in this signaling pathway.
Rapamycin (RAPA) is a novel macrolide immunosuppressant is now often used as a transplanted organ to maintain immunity drugs
(especially kidney transplants), to mitigate the immune organ rejection after transplant surgery, but scientists it recently found another
purpose: for the treatment of Alzheimer's disease (senile dementia).
Target of rapamycin (mTOR) as an intracellular kinases pathway abnormalities can induce a variety of diseases. As rapamycin mTOR
inhibitor targeting, to treat with this pathway is closely related to tumors, including renal cell carcinoma, lymphoma, lung cancer,
liver cancer, breast cancer, neuroendocrine carcinoma and gastric cancer